New combo therapy aims to control early lung cancer without surgery

This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or stereotactic radiation can help control early-stage non-small cell lung cancer in people who cannot have surgery or choose not to. About 45 participants with specific EGFR gene mutations will receive the combination and be followed for up to 3 years to see if it prevents the cancer from growing or coming back. The goal is to improve survival and reduce recurrence without needing surgery.